Updated threshold dose-distribution data for sesame

Paul J. Turner; Magdalena Gretzinger; Nandinee Patel; Helen A. Brough; R. Sharon Chinthrajah; Motohiro Ebisawa; Arnon Elizur; Jennifer J. Koplin; Rachel L. Peters; Natasha Purington; Anna Nowak-Wegrzyn; Sarah Saf; Hugh A. Sampson; Joost Westerhout; W. Marty Blom; Joseph L. Baumert; Geert F. Houben; Benjamin C. Remington

doi:10.1111/all.15364

Updated threshold dose-distribution data for sesame

Paul J. Turner^*, Magdalena Gretzinger, Nandinee Patel, Helen A. Brough, R. Sharon Chinthrajah, Motohiro Ebisawa, Arnon Elizur, Jennifer J. Koplin, Rachel L. Peters, Natasha Purington, Anna Nowak-Wegrzyn, Sarah Saf, Hugh A. Sampson, Joost Westerhout, W. Marty Blom, Joseph L. Baumert, Geert F. Houben, Benjamin C. Remington

^*Corresponding author for this work

Women & Children's Health

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	3124-3162
Number of pages	39
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	77
Issue number	10
DOIs	https://doi.org/10.1111/all.15364
Publication status	Published - Oct 2022

Access to Document

10.1111/all.15364

Cite this

Turner, P. J., Gretzinger, M., Patel, N., Brough, H. A., Chinthrajah, R. S., Ebisawa, M., Elizur, A., Koplin, J. J., Peters, R. L., Purington, N., Nowak-Wegrzyn, A., Saf, S., Sampson, H. A., Westerhout, J., Blom, W. M., Baumert, J. L., Houben, G. F., & Remington, B. C. (2022). Updated threshold dose-distribution data for sesame. Allergy: European Journal of Allergy and Clinical Immunology, 77(10), 3124-3162. https://doi.org/10.1111/all.15364

@article{e5bdb46a0cc8452297bf946b235182ea,

title = "Updated threshold dose-distribution data for sesame",

author = "Turner, {Paul J.} and Magdalena Gretzinger and Nandinee Patel and Brough, {Helen A.} and Chinthrajah, {R. Sharon} and Motohiro Ebisawa and Arnon Elizur and Koplin, {Jennifer J.} and Peters, {Rachel L.} and Natasha Purington and Anna Nowak-Wegrzyn and Sarah Saf and Sampson, {Hugh A.} and Joost Westerhout and Blom, {W. Marty} and Baumert, {Joseph L.} and Houben, {Geert F.} and Remington, {Benjamin C.}",

note = "Funding Information: RLP and JK receive research support from the National Health and Medical Research Council of Australia. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health. Funding Information: P.J. Turner reports personal fees from Aimmune Therapeutics, Allergenis, Aquestive, and UK Food Standards Agency pe; grants from NIHR/Imperial BRC, UK Medical Research Council, UK Food Standards Agency, Jon Moulton Charity Trust, outside the submitted work. H. Brough declares speaker fees from DBV Technologies and Sanofi, and research grants from NIH (NAIAD), DBV Technologies and Aimmune Therapeutics. S. Chinthrajah reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, FARE, Stanford Maternal and Child Health Research Institute (MCHRI); other support from Alladapt Therapeutics, Novartis, Genentech, Sanofi, Allergenis, Nutricia, outside the submitted work. M. Ebisawa reports personal fees from DBV Technologies, Mylan, ARS Pharmaceuticals, outside the submitted work. J. Koplin and R. Peters receive research support from the National Health and Medical Research Council of Australia. A. Nowak‐Wegrzyn reports royalty payments from UpToDate; personal fees from the American College of Allergy, Asthma, and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology; consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. H. Sampson reports grants from Immune Tolerance Network, NIAID/NIH, personal fees and other support from N‐Fold Therapeutics, DBV Technologies, and personal fees from Siolta Therapeutics, outside the submitted work. J Westerhout, WM Blom and GF Houben report financial support from Dutch Governmental TNO Research Cooperation Funds, Netherlands, and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska, USA. BC Remington reports grants from FARRP, grants and personal fees from DBV Technologies, and travel support from ILSI Europe, outside the submitted work. The other authors declare no competing interests. Funding Information: P.J. Turner reports personal fees from Aimmune Therapeutics, Allergenis, Aquestive, and UK Food Standards Agency pe; grants from NIHR/Imperial BRC, UK Medical Research Council, UK Food Standards Agency, Jon Moulton Charity Trust, outside the submitted work. H. Brough declares speaker fees from DBV Technologies and Sanofi, and research grants from NIH (NAIAD), DBV Technologies and Aimmune Therapeutics. S. Chinthrajah reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, FARE, Stanford Maternal and Child Health Research Institute (MCHRI); other support from Alladapt Therapeutics, Novartis, Genentech, Sanofi, Allergenis, Nutricia, outside the submitted work. M. Ebisawa reports personal fees from DBV Technologies, Mylan, ARS Pharmaceuticals, outside the submitted work. J. Koplin and R. Peters receive research support from the National Health and Medical Research Council of Australia. A. Nowak-Wegrzyn reports royalty payments from UpToDate; personal fees from the American College of Allergy, Asthma, and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology; consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. H. Sampson reports grants from Immune Tolerance Network, NIAID/NIH, personal fees and other support from N-Fold Therapeutics, DBV Technologies, and personal fees from Siolta Therapeutics, outside the submitted work. J Westerhout, WM Blom and GF Houben report financial support from Dutch Governmental TNO Research Cooperation Funds, Netherlands, and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska, USA. BC Remington reports grants from FARRP, grants and personal fees from DBV Technologies, and travel support from ILSI Europe, outside the submitted work. The other authors declare no competing interests. RLP and JK receive research support from the National Health and Medical Research Council of Australia. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health.",

year = "2022",

month = oct,

doi = "10.1111/all.15364",

language = "English",

volume = "77",

pages = "3124--3162",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "John Wiley and sons",

number = "10",

}

Turner, PJ, Gretzinger, M, Patel, N, Brough, HA, Chinthrajah, RS, Ebisawa, M, Elizur, A, Koplin, JJ, Peters, RL, Purington, N, Nowak-Wegrzyn, A, Saf, S, Sampson, HA, Westerhout, J, Blom, WM, Baumert, JL, Houben, GF & Remington, BC 2022, 'Updated threshold dose-distribution data for sesame', Allergy: European Journal of Allergy and Clinical Immunology, vol. 77, no. 10, pp. 3124-3162. https://doi.org/10.1111/all.15364

TY - JOUR

T1 - Updated threshold dose-distribution data for sesame

AU - Turner, Paul J.

AU - Gretzinger, Magdalena

AU - Patel, Nandinee

AU - Brough, Helen A.

AU - Chinthrajah, R. Sharon

AU - Ebisawa, Motohiro

AU - Elizur, Arnon

AU - Koplin, Jennifer J.

AU - Peters, Rachel L.

AU - Purington, Natasha

AU - Nowak-Wegrzyn, Anna

AU - Saf, Sarah

AU - Sampson, Hugh A.

AU - Westerhout, Joost

AU - Blom, W. Marty

AU - Baumert, Joseph L.

AU - Houben, Geert F.

AU - Remington, Benjamin C.

N1 - Funding Information: RLP and JK receive research support from the National Health and Medical Research Council of Australia. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health. Funding Information: P.J. Turner reports personal fees from Aimmune Therapeutics, Allergenis, Aquestive, and UK Food Standards Agency pe; grants from NIHR/Imperial BRC, UK Medical Research Council, UK Food Standards Agency, Jon Moulton Charity Trust, outside the submitted work. H. Brough declares speaker fees from DBV Technologies and Sanofi, and research grants from NIH (NAIAD), DBV Technologies and Aimmune Therapeutics. S. Chinthrajah reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, FARE, Stanford Maternal and Child Health Research Institute (MCHRI); other support from Alladapt Therapeutics, Novartis, Genentech, Sanofi, Allergenis, Nutricia, outside the submitted work. M. Ebisawa reports personal fees from DBV Technologies, Mylan, ARS Pharmaceuticals, outside the submitted work. J. Koplin and R. Peters receive research support from the National Health and Medical Research Council of Australia. A. Nowak‐Wegrzyn reports royalty payments from UpToDate; personal fees from the American College of Allergy, Asthma, and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology; consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. H. Sampson reports grants from Immune Tolerance Network, NIAID/NIH, personal fees and other support from N‐Fold Therapeutics, DBV Technologies, and personal fees from Siolta Therapeutics, outside the submitted work. J Westerhout, WM Blom and GF Houben report financial support from Dutch Governmental TNO Research Cooperation Funds, Netherlands, and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska, USA. BC Remington reports grants from FARRP, grants and personal fees from DBV Technologies, and travel support from ILSI Europe, outside the submitted work. The other authors declare no competing interests. Funding Information: P.J. Turner reports personal fees from Aimmune Therapeutics, Allergenis, Aquestive, and UK Food Standards Agency pe; grants from NIHR/Imperial BRC, UK Medical Research Council, UK Food Standards Agency, Jon Moulton Charity Trust, outside the submitted work. H. Brough declares speaker fees from DBV Technologies and Sanofi, and research grants from NIH (NAIAD), DBV Technologies and Aimmune Therapeutics. S. Chinthrajah reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, FARE, Stanford Maternal and Child Health Research Institute (MCHRI); other support from Alladapt Therapeutics, Novartis, Genentech, Sanofi, Allergenis, Nutricia, outside the submitted work. M. Ebisawa reports personal fees from DBV Technologies, Mylan, ARS Pharmaceuticals, outside the submitted work. J. Koplin and R. Peters receive research support from the National Health and Medical Research Council of Australia. A. Nowak-Wegrzyn reports royalty payments from UpToDate; personal fees from the American College of Allergy, Asthma, and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology; consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. H. Sampson reports grants from Immune Tolerance Network, NIAID/NIH, personal fees and other support from N-Fold Therapeutics, DBV Technologies, and personal fees from Siolta Therapeutics, outside the submitted work. J Westerhout, WM Blom and GF Houben report financial support from Dutch Governmental TNO Research Cooperation Funds, Netherlands, and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska, USA. BC Remington reports grants from FARRP, grants and personal fees from DBV Technologies, and travel support from ILSI Europe, outside the submitted work. The other authors declare no competing interests. RLP and JK receive research support from the National Health and Medical Research Council of Australia. NP and PJT are supported through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85130501989&partnerID=8YFLogxK

U2 - 10.1111/all.15364

DO - 10.1111/all.15364

M3 - Letter

C2 - 35531634

AN - SCOPUS:85130501989

SN - 0105-4538

VL - 77

SP - 3124

EP - 3162

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 10

ER -

Updated threshold dose-distribution data for sesame

Access to Document

Other files and links

Cite this